Mr. Seckman goes to Washington
This article was originally published in The Tan Sheet
Executive Summary
NNFA Executive Director & CEO David Seckman's lobbying efforts have targeted members of House Energy & Commerce Committee, which is investigating supplements including ephedra and andro. NNFA reports Seckman visited more than 30 Congressional offices in his first week in Washington, D.C. to educate members, staff on DSHEA and to promote message that FDA has sufficient authority to regulate supplements. Seckman also met with FDA Deputy Commissioner Lester Crawford, PhD, and others May 23 to discuss andro and other issues, such as FDA's authority under DSHEA. NNFA opened Washington office in April (1"The Tan Sheet" May 5, 2003, In Brief)...
You may also be interested in...
NNFA opens D.C. office
Trade group's Washington, D.C. office opened April 30 to "expand advocacy efforts with federal legislators and regulators on behalf of its members and the natural products industry." NNFA Executive Director & CEO David Seckman is first to relocate to the new office, "which will initially deal primarily with government relations and public affairs," group says. NNFA, which has been planning the move for more than a year, will evaluate its staffing needs as time goes on; group retains its Newport Beach, Calif. office. D.C. branch is located at 1220 19th St. NW, Suite 400...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.